Leuprolide Acetate side effects: what 77,109 FDA adverse event reports show
Drug class
Gonadotropin-releasing hormone (gnrh) agonist
Brand names
Camcevi
Who reports
77,109 reports · 46% serious · 12,049 with death outcome · 23% female
Used for
CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.
What it is
CAMCEVI is a sterile formulation of leuprolide mesylate for subcutaneous injection. CAMCEVI is designed to deliver approximately 42 mg of leuprolide over 6 months. Leuprolide mesylate is a synthetic nonapeptide analog of naturally occurring GnRH and is a GnRH agonist.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,166 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Intercepted product preparation error | 9,222 | 881.5 845.5–919.0ROR 1,001.1 · calibrated p 2e-17 ✓ | 205.8 EB05 202.3 · IC025 +7.6 3/3 methods agree | Not in label — unassessed | serious n=41 · 97% clinician | not reported in cached trials |
| Injection site abscess sterile | 60 | 334.2 228.7–488.4ROR 334.5 · calibrated p 2e-11 ✓ | 142.4 EB05 114.7 · IC025 +5.6 3/3 methods agree | Labeled (related wording) related wording | serious n=18 · ♀ 60% (drug 23%) · 100% clinician | not reported in cached trials |
| Bulbospinal muscular atrophy congenital | 21 | 267.4 146.0–489.5ROR 267.4 · calibrated p 9e-10 ✓ | 119.8 EB05 82.7 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=20 · ♀ 0% (drug 23%) · 100% clinician | not reported in cached trials |
| Syringe issue | 7,900 | 224.8 218.3–231.4ROR 250.3 · calibrated p 5e-11 ✓ | 122.5 EB05 120.3 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=64 · 93% clinician | not reported in cached trials |
| Prostatic specific antigen abnormal | 447 | 204.3 180.7–231.0ROR 205.5 · calibrated p 4e-10 ✓ | 115.7 EB05 106.9 · IC025 +6.5 3/3 methods agree | Lab value / disease marker | serious n=222 · ♀ 0% (drug 23%) | NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE) |
| Abscess sterile | 55 | 173.0 123.2–242.8ROR 173.1 · calibrated p 4e-9 ✓ | 101.8 EB05 81.1 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=15 · ♀ 100% (drug 23%) · 100% clinician | not reported in cached trials |
| Blood luteinising hormone abnormal | 20 | 172.5 98.3–302.6ROR 172.5 · calibrated p 2e-8 ✓ | 95.9 EB05 65.5 · IC025 +4.1 3/3 methods agree | Lab value / disease marker | – | not reported in cached trials |
| Blood testosterone abnormal | 385 | 143.4 126.7–162.2ROR 144.1 · calibrated p 7e-9 ✓ | 93.2 EB05 85.7 · IC025 +6.2 3/3 methods agree | Lab value / disease marker | serious n=173 · ♀ 0% (drug 23%) | not reported in cached trials |
| Intercepted medication error | 1,131 | 86.7 81.1–92.7ROR 88.0 · calibrated p 3e-7 ✓ | 65.7 EB05 62.5 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Prostate cancer metastatic | 684 | 69.7 64.1–75.8ROR 70.3 · calibrated p 1e-6 ✓ | 55.4 EB05 52.0 · IC025 +5.6 3/3 methods agree | Labeled (related wording) related wording | serious n=682 · ♀ 0% (drug 23%) | NCT01081873: 5/2,714 (0.2%) on Leuprolide (serious AE) |
| Blood testosterone increased | 429 | 67.5 60.7–75.0ROR 67.8 · calibrated p 2e-6 ✓ | 54.0 EB05 49.8 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=207 · ♀ 0% (drug 23%) | not reported in cached trials |
| Prostatic specific antigen increased | 2,421 | 57.5 55.1–60.1ROR 59.4 · calibrated p 4e-6 ✓ | 47.5 EB05 45.9 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious PRR 66.5 · ♀ 0% (drug 23%) | NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE) |
| Product physical consistency issue | 951 | 57.2 53.3–61.3ROR 57.9 · calibrated p 5e-6 ✓ | 47.2 EB05 44.8 · IC025 +5.4 3/3 methods agree | Reporting / coding artifact | 94% clinician | not reported in cached trials |
| Radiation proctitis | 31 | 53.8 36.6–79.2ROR 53.8 · calibrated p 2e-5 ✓ | 43.8 EB05 32.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=27 · ♀ 0% (drug 23%) | not reported in cached trials |
| Endometriosis | 772 | 52.4 48.6–56.6ROR 53.0 · calibrated p 1e-5 ✓ | 44.0 EB05 41.4 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=519 · ♀ 100% (drug 23%) · 75% consumer | not reported in cached trials |
| Laparoscopy | 41 | 52.0 37.2–72.6ROR 52.0 · calibrated p 2e-5 ✓ | 42.9 EB05 32.9 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=40 · ♀ 100% (drug 23%) · 100% consumer | not reported in cached trials |
| Child abuse | 38 | 48.6 34.4–68.7ROR 48.6 · calibrated p 3e-5 ✓ | 40.5 EB05 30.8 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | serious n=38 · ♀ 0% (drug 23%) · 100% clinician | not reported in cached trials |
| Device leakage | 6,230 | 46.9 45.7–48.1ROR 50.9 · calibrated p 1e-5 ✓ | 40.0 EB05 39.2 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | serious n=40 · 97% clinician | not reported in cached trials |
| Hormone-refractory prostate cancer | 171 | 46.3 39.4–54.5ROR 46.4 · calibrated p 2e-5 ✓ | 39.5 EB05 34.7 · IC025 +4.9 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=170 · ♀ 0% (drug 23%) | not reported in cached trials |
| Prostate cancer recurrent | 89 | 46.0 36.8–57.6ROR 46.1 · calibrated p 3e-5 ✓ | 39.1 EB05 32.8 · IC025 +4.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=89 · ♀ 0% (drug 23%) | not reported in cached trials |
| Cystitis radiation | 27 | 44.3 29.5–66.5ROR 44.3 · calibrated p 6e-5 ✓ | 37.2 EB05 26.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=26 · ♀ 0% (drug 23%) | not reported in cached trials |
| Product reconstitution quality issue | 120 | 43.8 36.1–53.1ROR 43.8 · calibrated p 4e-5 ✓ | 37.5 EB05 32.2 · IC025 +4.7 3/3 methods agree | Reporting / coding artifact | ♀ 0% (drug 23%) | not reported in cached trials |
| Victim of child abuse | 34 | 43.3 30.1–62.2ROR 43.3 · calibrated p 6e-5 ✓ | 36.7 EB05 27.5 · IC025 +4.0 3/3 methods agree | Reporting / coding artifact | serious n=34 · ♀ 0% (drug 23%) · 100% clinician | not reported in cached trials |
| Epidural lipomatosis | 47 | 42.3 31.1–57.5ROR 42.3 · calibrated p 6e-5 ✓ | 36.2 EB05 28.3 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=47 · ♀ 0% (drug 23%) · 100% clinician | not reported in cached trials |
| Hot flush (hot flashes) | 9,564 | 39.4 38.7–40.2ROR 44.9 · calibrated p 3e-5 ✓ | 34.5 EB05 33.9 · IC025 +5.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 28.1 · 84% consumer | NCT01081873: 2/2,714 (0.1%) on Leuprolide |
| Palliative care | 191 | 38.7 33.2–45.0ROR 38.7 · calibrated p 7e-5 ✓ | 33.8 EB05 30.0 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=191 · ♀ 0% (drug 23%) | not reported in cached trials |
| Prostatic specific antigen decreased | 47 | 38.3 28.2–52.0ROR 38.3 · calibrated p 1e-4 ✓ | 33.2 EB05 26.0 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=26 · ♀ 0% (drug 23%) · 100% consumer | NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE) |
| Product administered by wrong person | 43 | 35.9 26.1–49.4ROR 35.9 · calibrated p 1e-4 ✓ | 31.4 EB05 24.3 · IC025 +4.0 3/3 methods agree | Reporting / coding artifact | – | not reported in cached trials |
| Blood luteinising hormone increased | 28 | 34.7 23.4–51.4ROR 34.7 · calibrated p 2e-4 ✓ | 30.2 EB05 21.9 · IC025 +3.7 3/3 methods agree | Lab value / disease marker | ♀ 100% (drug 23%) · 100% clinician | not reported in cached trials |
| Injection site granuloma | 23 | 30.1 19.6–46.4ROR 30.2 · calibrated p 5e-4 ✓ | 26.7 EB05 18.7 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | serious n=16 | not reported in cached trials |
| Oestradiol increased | 29 | 29.1 19.9–42.8ROR 29.2 · calibrated p 5e-4 ✓ | 26.0 EB05 19.0 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | ♀ 100% (drug 23%) · 100% clinician | not reported in cached trials |
| Post procedural diarrhoea | 49 | 28.9 21.5–38.8ROR 28.9 · calibrated p 4e-4 ✓ | 26.0 EB05 20.4 · IC025 +3.9 3/3 methods agree | Reporting / coding artifact | serious n=15 · ♀ 0% (drug 23%) · 73% consumer | not reported in cached trials |
| Terminal state | 641 | 28.7 26.4–31.1ROR 28.9 · calibrated p 3e-4 ✓ | 26.0 EB05 24.3 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=639 · ♀ 0% (drug 23%) · 75% consumer | NCT01081873: 2/2,714 (0.1%) on Leuprolide (serious AE) |
| Testicular atrophy | 76 | 25.9 20.5–32.8ROR 26.0 · calibrated p 7e-4 ✓ | 23.6 EB05 19.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=29 · ♀ 0% (drug 23%) · 82% consumer | not reported in cached trials |
| Adnexa uteri pain | 103 | 23.8 19.5–29.1ROR 23.8 · calibrated p 1e-3 ✓ | 21.9 EB05 18.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=31 · ♀ 100% (drug 23%) · 83% consumer | not reported in cached trials |
| Metastases to bladder | 22 | 22.7 14.7–35.1ROR 22.7 · calibrated p 0.002 ✓ | 20.6 EB05 14.3 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=22 · ♀ 0% (drug 23%) | NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE) |
| Menstruation normal | 24 | 22.0 14.5–33.4ROR 22.1 · calibrated p 0.002 ✓ | 20.1 EB05 14.1 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | ♀ 100% (drug 23%) · 100% consumer | not reported in cached trials |
| Lipid metabolism disorder | 27 | 22.0 14.9–32.6ROR 22.0 · calibrated p 0.002 ✓ | 20.1 EB05 14.5 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=24 · ♀ 0% (drug 23%) · 100% clinician | not reported in cached trials |
| Device connection issue | 153 | 21.8 18.5–25.7ROR 21.9 · calibrated p 0.001 ✓ | 20.2 EB05 17.7 · IC025 +4.0 3/3 methods agree | Reporting / coding artifact | ♀ 0% (drug 23%) · 100% clinician | not reported in cached trials |
| Injection site abscess | 182 | 21.5 18.5–24.9ROR 21.5 · calibrated p 0.001 ✓ | 19.9 EB05 17.6 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=80 · ♀ 54% (drug 23%) | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Leuprolide as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (7 of 40 signal terms matched).
- NCT01081873 — Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the (N=2717, phase n/a; 113 AE terms posted; arms: Advanced Prostate Cancer Participants)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Hot flush (hot flashes) | 9,564 | 39.4 38.7–40.2ROR 44.9 · calibrated p 3e-5 ✓ | 34.5 EB05 33.9 · IC025 +5.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 28.1 · 84% consumer | NCT01081873: 2/2,714 (0.1%) on Leuprolide |
| Intercepted product preparation error | 9,222 | 881.5 845.5–919.0ROR 1,001.1 · calibrated p 2e-17 ✓ | 205.8 EB05 202.3 · IC025 +7.6 3/3 methods agree | Not in label — unassessed | serious n=41 · 97% clinician | not reported in cached trials |
| Death | 8,528 | 2.7 2.7–2.8ROR 2.9 · calibrated p 0.652 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Outcome field, not a reaction | serious PRR 3.4 · ♀ 1% (drug 23%) | NCT01081873: 8/2,714 (0.3%) on Leuprolide (serious AE) |
| Syringe issue | 7,900 | 224.8 218.3–231.4ROR 250.3 · calibrated p 5e-11 ✓ | 122.5 EB05 120.3 · IC025 +6.9 3/3 methods agree | Not in label — unassessed | serious n=64 · 93% clinician | not reported in cached trials |
| Device leakage | 6,230 | 46.9 45.7–48.1ROR 50.9 · calibrated p 1e-5 ✓ | 40.0 EB05 39.2 · IC025 +5.3 3/3 methods agree | Reporting / coding artifact | serious n=40 · 97% clinician | not reported in cached trials |
| Wrong technique in product usage process | 5,461 | 7.5 7.3–7.7ROR 8.0 · calibrated p 0.066 | 7.3 EB05 7.2 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | serious PRR 0.7 | not reported in cached trials |
| Fatigue (tiredness) | 5,098 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.857 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | serious PRR 1.9 · 77% consumer | NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE) |
| Injection site pain (pain where injected) | 4,870 | 4.4 4.3–4.5ROR 4.6 · calibrated p 0.276 | 4.4 EB05 4.3 · IC025 +2.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 6.9 · 85% consumer | not reported in cached trials |
| Prostatic specific antigen increased | 2,421 | 57.5 55.1–60.1ROR 59.4 · calibrated p 4e-6 ✓ | 47.5 EB05 45.9 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious PRR 66.5 · ♀ 0% (drug 23%) | NCT01081873: 1/2,714 (0.0%) on Leuprolide (serious AE) |
| Asthenia (weakness) | 2,406 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.811 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 2.0 · 70% consumer | not reported in cached trials |
| Off label use (used outside approved label) | 2,350 | 0.7 0.7–0.8ROR 0.7 · calibrated p 0.144 | 0.7 EB05 0.7 · IC025 -0.5 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 0.6 · ♀ 61% (drug 23%) | not reported in cached trials |
| Drug ineffective (drug did not work) | 2,280 | 0.5 0.5–0.5ROR 0.5 · calibrated p 0.035 ✓ | 0.5 EB05 0.5 · IC025 -1.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 0.8 | not reported in cached trials |
| Fall | 1,994 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.739 | 1.6 EB05 1.6 · IC025 +0.6 | Not in label — unassessed | serious PRR 2.2 | not reported in cached trials |
| Arthralgia (joint pain) | 1,964 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.507 | 1.3 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | serious PRR 1.3 · 71% consumer | not reported in cached trials |
| Pain | 1,935 | 0.9 0.8–0.9ROR 0.9 · calibrated p 0.213 | 0.9 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC | Labeled adverse reaction exact term | serious PRR 1.0 · ♀ 47% (drug 23%) | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Intercepted product preparation error — n=9,222, PRR 881.5
- Bulbospinal muscular atrophy congenital — n=21, PRR 267.4
- Syringe issue — n=7,900, PRR 224.8
- Abscess sterile — n=55, PRR 173.0
- Intercepted medication error — n=1,131, PRR 86.7
- Radiation proctitis — n=31, PRR 53.8
- Endometriosis — n=772, PRR 52.4
- Laparoscopy — n=41, PRR 52.0
- Cystitis radiation — n=27, PRR 44.3
- Epidural lipomatosis — n=47, PRR 42.3
✓ A hand-written Bradford Hill causality assessment exists for this drug: Medroxyprogesterone acetate ↔ Meningioma.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Leuprolide?
In FDA FAERS, the most frequently co-reported reaction terms for Leuprolide are hot flush, intercepted product preparation error, syringe issue, fatigue, injection site pain, prostatic specific antigen increased. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Leuprolide have an FDA boxed warning?
No. The FDA label retrieved for Leuprolide has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Leuprolide causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID d7a8761a-d953-413a-e053-2a95a90a60ee, effective 20260218; matched on
openfda.generic_name.exact:"LEUPROLIDE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,206 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
LEUPROLIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.